- Went public, Sep 2020
- Acquired LayerBio, Aug 2025
- Raised $6M funding round, Mar 2021
About
PainReform is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics. Its proprietary drug-delivery system is designed to provide an extended period of post-surgical pain relief without the need for repeated dose administration while also reducing the use of opiates commonly administered after surgery. The companys strategy is to incorporate generic drugs which have been proven safe and effective with its proprietary extended-release drug-delivery system in order to create a major improvement in therapy via extended-release drug products and to take advantage of the 505(b)(2) regulatory pathway created by the U.S. Food and Drug Administration (FDA). The 505(b)(2) new drug application process provides for FDA approval of a new drug based in part on data developed by others, including references in published literature and data previously reviewed by the FDA in its approval of a separate application. This pathway can significantly reduce future time and costs associated with clinical development. PainReforms first product, PRF-110, is based on the local anesthetic ropivacaine and is designed to target the post-operative pain relief market.
Funding history · 3 rounds · $46.3M total
Q&A
- When did PainReform become a public company?
- PainReform became public on NASDAQ in September 2020.
- What is PainReform's primary focus?
- PainReform is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, specifically for extended post-surgical pain relief.
- What is PainReform's first product?
- PainReform's first product, PRF-110, is based on the local anesthetic ropivacaine and is designed to target the post-operative pain relief market.
- What was the amount of PainReform's public offering in April 2024?
- In April 2024, PainReform closed a public offering of $4,000,000.
- What was the amount of PainReform's public offering in September 2020?
- In September 2020, PainReform had a public offering of $23,000,000.
- What is the employee count for PainReform?
- PainReform has 1-10 employees.
- Who is the co-founder of PainReform?
- Oren Shuster is a co-founder of PainReform.
- What was the total amount raised by PainReform through funding rounds?
- PainReform has raised a total of $46,300,000 through funding rounds.
Team · 1
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | prf-tech.com |
|---|---|
| linkedin.com/company/689691 |
Identifiers & details
| Founded | 2007-12 |
|---|---|
| Employees (exact) | 7 |
| Market cap | $2.5M |
| Status reason | Public on NASDAQ on Sep, 2020; |
Acquisitions & public offerings
| Acquired | Date | Amount |
|---|---|---|
| LayerBio | 2025-08 |
| Type | Date | Exchange | Ticker | Amount |
|---|---|---|---|---|
| 2024-04 | $4.0M | |||
| 2020-09 | $23.0M |